<DOC>
	<DOCNO>NCT01309477</DOCNO>
	<brief_summary>It pilot study explore efficacy safety Tacrolimus Sustained-release Capsules ( ADVAGRAF ) 6-month induction therapy Refractory Nephrotic Syndrome ( RNS ) .</brief_summary>
	<brief_title>The Efficacy Tolerance Tacrolimus Sustained-release Capsules Refractory Nephrotic Syndrome ( RNS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Nephrotic Syndrome</mesh_term>
	<mesh_term>Nephrosis</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Subjects either sex , 1460 year age Diagnosis Nephrotic syndrome hypoalbuminemia ( &lt; 3.0g/dl ) heavy proteinuria ( &gt; 3.5g/24hr ) exclude secondary Nephrotic syndrome Refractory Nephrotic Syndrome 1 . Steroid resistant : failure respond ( either complete partial remission ) course 8 week 1.0 mg/kg/d prednisone equal dose steroid therapy 2 . Steroid dependent : recurrence nephrotic proteinuria taper prednisone dose &gt; 10 mg/day within first 2 week withdrawal prednisone 3 . Frequently recurrence : initial remission steroid induction therapy , relapse 2 6 month 3 within 12 month 4 . Failure respond ( either complete partial remission ) even CTX , MMF CsA therapy combine steroid eGFR â‰¥ 60 ml/min/1.73 m2 Provision write informed consent subject guardian Systemic disease eGFR &lt; 60ml/min/1.73m2 Diagnosed DM Malignant tumor ( except fully cure basal cell carcinoma ) Familial nephritic syndrome History significant gastrointestinal disorder ( e.g . severe chronic diarrhea active peptic ulcer disease ) within 3 month prior enter study Any Active systemic infection history serious infection within one month entry know infection HIV , hepatitis B , hepatitis C Known hypersensitivity contraindication tacrolimus , corticosteroid Participation another clinic trial and/or receipt investigational drug within 4 week prior screen Pregnancy , nursing use nonreliable method contraception Inability unwillingness provide write informed consent Usage immunosuppression therapy ( MMF , CTX , CysA , MTX ect ) 1 week within 1 month prior first randomization intravenous MP Pulse treatment</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Refractory Nephrotic Syndrome</keyword>
	<keyword>Tacrolimus</keyword>
</DOC>